RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...
112 N Bayshore Blvd #3 San Mateo, Ca 94401
650-544-0793
jamesfgraham111@gmail.com
Copyright © 2024 botnik. All Rights Reserved
